Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes.

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations ... that may be related to dosing errors ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...